HRP20040107B1 - Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova - Google Patents

Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova

Info

Publication number
HRP20040107B1
HRP20040107B1 HR20040107A HRP20040107A HRP20040107B1 HR P20040107 B1 HRP20040107 B1 HR P20040107B1 HR 20040107 A HR20040107 A HR 20040107A HR P20040107 A HRP20040107 A HR P20040107A HR P20040107 B1 HRP20040107 B1 HR P20040107B1
Authority
HR
Croatia
Prior art keywords
polymorph
flibanserine
medicines
stable
preparation
Prior art date
Application number
HR20040107A
Other languages
English (en)
Croatian (hr)
Inventor
Bombarda Carlo
Dubini Enrica
Ezhaya Antoine
Schneider Heinrich
Original Assignee
Bidachem S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem S.P.A. filed Critical Bidachem S.P.A.
Publication of HRP20040107A2 publication Critical patent/HRP20040107A2/hr
Publication of HRP20040107B1 publication Critical patent/HRP20040107B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HR20040107A 2001-08-02 2002-07-30 Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova HRP20040107B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (2)

Publication Number Publication Date
HRP20040107A2 HRP20040107A2 (en) 2004-06-30
HRP20040107B1 true HRP20040107B1 (hr) 2012-02-29

Family

ID=26076670

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040107A HRP20040107B1 (hr) 2001-08-02 2002-07-30 Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova

Country Status (26)

Country Link
EP (2) EP1414816B1 (OSRAM)
JP (1) JP3822601B2 (OSRAM)
KR (1) KR100899297B1 (OSRAM)
CN (1) CN1288147C (OSRAM)
AR (2) AR036208A1 (OSRAM)
AT (1) ATE288911T1 (OSRAM)
AU (1) AU2002331361B2 (OSRAM)
BR (1) BR0211601A (OSRAM)
CA (1) CA2450093C (OSRAM)
CO (1) CO5560572A2 (OSRAM)
DE (1) DE60202958T2 (OSRAM)
DK (1) DK1414816T3 (OSRAM)
EA (1) EA006400B1 (OSRAM)
ES (1) ES2237694T3 (OSRAM)
HR (1) HRP20040107B1 (OSRAM)
HU (1) HU228666B1 (OSRAM)
IL (2) IL159151A0 (OSRAM)
MX (1) MXPA04000913A (OSRAM)
MY (1) MY127294A (OSRAM)
NZ (1) NZ530510A (OSRAM)
PL (1) PL210224B1 (OSRAM)
PT (1) PT1414816E (OSRAM)
RS (1) RS50742B (OSRAM)
SI (1) SI1414816T1 (OSRAM)
UA (1) UA76767C2 (OSRAM)
WO (1) WO2003014079A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
NZ537253A (en) * 2002-05-22 2007-09-28 Boehringer Ingelheim Pharma Coated pharmaceutical compositions containing flibanserin polymorph A
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
WO2008019996A2 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5220746B2 (ja) 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Also Published As

Publication number Publication date
CN1551879A (zh) 2004-12-01
PT1414816E (pt) 2005-04-29
IL159151A0 (en) 2004-06-01
DE60202958T2 (de) 2006-04-06
PL364598A1 (en) 2004-12-13
SI1414816T1 (en) 2005-06-30
KR20040023704A (ko) 2004-03-18
EA006400B1 (ru) 2005-12-29
DE60202958D1 (de) 2005-03-17
EP1518858A1 (en) 2005-03-30
CO5560572A2 (es) 2005-09-30
MXPA04000913A (es) 2004-10-27
IL159151A (en) 2009-09-22
HRP20040107A2 (en) 2004-06-30
ES2237694T3 (es) 2005-08-01
JP2004537597A (ja) 2004-12-16
DK1414816T3 (da) 2005-04-11
WO2003014079A8 (en) 2003-11-20
CA2450093A1 (en) 2003-02-20
AU2002331361B2 (en) 2008-06-05
BR0211601A (pt) 2004-08-24
EA200400252A1 (ru) 2004-08-26
ATE288911T1 (de) 2005-02-15
KR100899297B1 (ko) 2009-05-26
YU7804A (sh) 2006-08-17
UA76767C2 (uk) 2006-09-15
RS50742B (sr) 2010-08-31
EP1414816A1 (en) 2004-05-06
MY127294A (en) 2006-11-30
NZ530510A (en) 2004-07-30
AR077416A2 (es) 2011-08-24
EP1414816B1 (en) 2005-02-09
JP3822601B2 (ja) 2006-09-20
AR036208A1 (es) 2004-08-18
HU228666B1 (en) 2013-05-28
HUP0401201A2 (hu) 2004-10-28
HK1070063A1 (en) 2005-06-10
PL210224B1 (pl) 2011-12-30
CN1288147C (zh) 2006-12-06
WO2003014079A1 (en) 2003-02-20
CA2450093C (en) 2008-09-23
HUP0401201A3 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
HRP20040107B1 (hr) Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
CY1109011T1 (el) ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ βd ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΔΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
NO20031694L (no) Krystallinsk monohydrat, fremgangsmåte for fremstilling derav og anvendelsederav til fremstilling av et medikament
MXPA03006001A (es) Derivados de fosfonato de nucleosido aciclico novedoso, sales de estos y proceso para la preparacion de los mismos.
IS6957A (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
HRP20030154B1 (en) Preparation of risperidone
HUP0401783A3 (en) 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands, their use and pharmaceutical compositions containing them
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
ATE291908T1 (de) Ibuprofen-wirkstoffzubereitung
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
ITUD20000163A0 (it) Dispositivo per la produzione di manufatti poliuretanici, relativo procedimento e manufatti poliuretanici cosi' ottenuti
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
NO20013060L (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
WO2003051398A8 (en) Parenteral composition of paracetamol
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
FR2848851B1 (fr) Procede d'obtention d'un principe actif presentant des capacites apaisantes, principe actif et compositions obtenues
NO20025461L (no) Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron
NO20040912L (no) Beskyttede 3,5-dihydroksy-2,2-dimetyl-valeroamider for syntese av epotiloner og derivater derav, og fremgangsmate for fremstilling og andvendelse derav.
NO20035642L (no) Fremgangsmate for fremstilling av derivater av 1,5-diaryl-3-trifluormetyl-delta2-pyrazoliner som er racemisk og enantiomerisk rene
NO20040426L (no) Nye imidazolidinderivater og deres fremstilling og andvendelse som VLA-4-antagonister.
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid
IT1318522B1 (it) Procedimento per la preparazione di agglomerati stabilizzati da ceneredi lolla e paglia di riso.
IT1318716B1 (it) Impianto per la produzione di calore accumulabile.
NO20040423L (no) Salter av substituerte 1,2,3,4-tetrahydroisokinolin-2-karboksylsyrederivater.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20140702

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20150730